

Study Name:
Eastern European Bladder Cancer Study

Principal Investigators:
Tony Fletcher

Key References:

Institution:
PEHRU Public and Environmental Health Research Unit
London School of Hygiene & Tropical Medicine
Institution address:
PEHRU Public and Environmental Health Research Unit,
London School of Hygiene & Tropical Medicine, Keppel
Street, London WC1E 7HT, UK
Additional researchers:

Study Design:
Hospital-based case control
ICD-0-3 morphology codes:

Matching factors:
Age, gender
Follow up of cases?
No

Country:
Hungary, Romania, Slovakia
Expected time of follow-up?
NA

Urinary Bladder ICD-0-3 morphology codes: Transitional cell carcinoma (81203); Papillary carcinoma (81303); Squamous cell carcinoma (80703); Adenocarcinoma (81403); Leiomyosarcoma (88903)

	Cases	Controls
Years of enrollment	2002-2004	2002-2004
Source population	Hungary, Romania and Slovakia	Hungary, Romania and Slovakia
Response rate (enrolled/eligible)	85.3%	
Total number enrolled	214	540
Subjects with DNA	214	540
Ethnic origin	Caucasian	Caucasian
Age: mean (range)	30-79	30-79
Gender: % males		

Questionnaire data	Cases	Controls
Demographics (age, sex, ethnicity, region, education etc..)	x	x
Active smoking	x	x
Passive smoking	x	x
Occupational exposures	x	x
Residential history	x	x
Water chlorination byproducts		
Arsenic exposure	x	x
Other environmental exposures		
Hair dye use		
Drug use	x	x
Medical History	x	x
Family History	x	x
Quality of life		
Diet/nutrition	x	x
Caffeine intake	x	x
Fluid intake	x	x
Urine pH measurements		
Other information, please specify	x	x

Biological Samples	Cases	Controls
Blood DNA	x	x
Buccal DNA	x	x
Serum/plasma		
Cryopreserved whole blood / lymphocytes		
Red blood cells		
Urine samples		
Toenail clippings		
Others, please specify		
Paraffin tissue blocks		
Frozen tissue		

For Cases Only

Information at time of diagnosis

Histological confirmation	x
Number of tumors	
Tumor site	
Tumor size	
Tumor grade	x
Growth pattern	
Treatment of primary tumor	
Stage	
Other information, please specify	

Follow-up information

Treatment information	
Tumor recurrence	
Tumor progression	
Survival	
Histological confirmation	
Number of tumors	
Tumor site	
Tumor size	
Tumor grade	
Growth pattern	
Stage	
Active smoking	
Occupational exposures	
Drug use	
Medical History	
Quality of life	
Caffeine intake	
Fluid intake	
Other information , please specify	